EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Priming of labor with tafoxiparin in nulliparous term pregnant women with unripe cervix—Proof‐of‐concept and dose‐finding results from a randomized controlled trial

Gunvor Ekman-Ordeberg iD, Maria Jonsson, Marie Blomberg iD, Malin Melin, Ylva Stjernholm-Vladic, Sebastian B Gidlöf, Dag Wide-Swensson, Kati Tihtonen, Inge C Olsen, Lena Degling-Wikingsson, Per Blom, Leena Rahkonen

Acta Obstetricia et Gynecologica Scandinavica · 2026-08 · 105 (8) · 1566-1577

DOI: 10.1111/aogs.70232 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, online erschienen am 14.05.2026. Verfasst von Gunvor Ekman-Ordeberg und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Karolinska Insitutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Cervical Ripening, Labor, Induced, Oxytocics. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dilafor AB, Solna, Sweden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

New therapies are needed to improve the risk–benefit profile of intervention for labor induction. Tafoxiparin, a depolymerized form of heparin with no anticoagulant effects, has demonstrated potential to increase cervical ripening and influence the onset and outcome of labor. We assessed the effects of tafoxiparin in women with an unripe cervix scheduled for labor induction. Material and Methods Phase 2 randomized double‐blind placebo‐controlled study (PPL17; EudraCT 2019‐000620‐17), conducted in two parts. The first part compared tafoxiparin 300 mg vs. placebo, while the second part assessed tafoxiparin 150 and 75 mg. Study treatment was administered once daily up to 7 days or until onset of labor or ripened cervix. Study participants were nulliparous women at term with an unripe cervix and planned labor induction. The primary endpoint was the cervical ripening rate during treatment, as measured by Bishop score.

Results

Of 348 randomized women, 347 received study treatment. The primary analysis of Bishop score showed statistically significant increases in cervical ripening with tafoxiparin. The difference from placebo was most pronounced in the 300 mg group (mean slope 0.86 vs. 0.62, p = 0.006). Spontaneous onset of labor occurred in 39.8%–42.4% of women treated with tafoxiparin versus 28.4% with placebo. The rate of instrumental vaginal deliveries (vacuum extractions) was lowest in the tafoxiparin 300 mg group (10.0% vs. 24.1% with placebo; p = 0.013). Few serious adverse events were reported, and there was no hypercontractility related to tafoxiparin.

Conclusions

Tafoxiparin was effective in cervical ripening, facilitating spontaneous onset of labor and reducing the need for instrumental delivery. Benefits were most pronounced with the 300 mg dose, and a favorable safety profile was observed. These results suggest that tafoxiparin may be suitable for obstetrical use in outpatient and home‐based settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cervical RipeningLabor, InducedOxytocicsHumansFemalePregnancyDouble-Blind MethodAdultParityDose-Response Relationship, DrugCervix UteriTreatment Outcome

Stichwörter der Autor:innen

Tafoxiparincervical ripeninghome treatmentlabor primingplaceborandomized controlled trialspontaneous onset of labor

Substanzen

Oxytocics

Autor:innen und Institutionen

  • Department of Women's and Children's Health, Karolinska Insitutet, Stockholm, Sweden.
  • Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
  • Department of Obstetrics and Gynecology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Obstetrics and Gynecology, Linköping University, Linköping, Sweden.
  • Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
  • Department of Obstetrics and Gynecology, Skaraborg Hospital, Skövde, Sweden.

ORCID-Profile: Gunvor Ekman-Ordeberg, Marie Blomberg

Förderung

  • Dilafor AB, Solna, Sweden

Zitieren

APA

Ekman-Ordeberg, G., Jonsson, M., Blomberg, M., Melin, M., Stjernholm-Vladic, Y., Gidlöf, S. B., Wide-Swensson, D., Tihtonen, K., Olsen, I. C., Degling-Wikingsson, L., Blom, P., & Rahkonen, L. (2026). Priming of labor with tafoxiparin in nulliparous term pregnant women with unripe cervix—Proof‐of‐concept and dose‐finding results from a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica, 105(8), 1566-1577. https://doi.org/10.1111/aogs.70232

Vancouver

Ekman-Ordeberg G, Jonsson M, Blomberg M, Melin M, Stjernholm-Vladic Y, Gidlöf SB, et al. Priming of labor with tafoxiparin in nulliparous term pregnant women with unripe cervix—Proof‐of‐concept and dose‐finding results from a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica. 2026;105(8):1566-1577. doi:10.1111/aogs.70232

BibTeX
@article{EkmanOrdeberg2026,
  author = {Ekman-Ordeberg, Gunvor and Jonsson, Maria and Blomberg, Marie and Melin, Malin and Stjernholm-Vladic, Ylva and Gidlöf, Sebastian B and Wide-Swensson, Dag and Tihtonen, Kati and Olsen, Inge C and Degling-Wikingsson, Lena and Blom, Per and Rahkonen, Leena},
  title = {Priming of labor with tafoxiparin in nulliparous term pregnant women with unripe cervix—Proof‐of‐concept and dose‐finding results from a randomized controlled trial},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2026},
  volume = {105},
  number = {8},
  pages = {1566--1577},
  doi = {10.1111/aogs.70232}
}
Kostenlos starten →